1. Home
  2. FLGT vs IVVD Comparison

FLGT vs IVVD Comparison

Compare FLGT & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fulgent Genetics Inc.

FLGT

Fulgent Genetics Inc.

HOLD

Current Price

$20.82

Market Cap

511.2M

Sector

Health Care

ML Signal

HOLD

Logo Invivyd Inc.

IVVD

Invivyd Inc.

HOLD

Current Price

$0.90

Market Cap

437.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLGT
IVVD
Founded
2011
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
511.2M
437.1M
IPO Year
2016
2021

Fundamental Metrics

Financial Performance
Metric
FLGT
IVVD
Price
$20.82
$0.90
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
$28.33
$8.75
AVG Volume (30 Days)
301.5K
6.3M
Earning Date
05-01-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
79.02
EPS
N/A
N/A
Revenue
$18,730,000.00
$53,426,000.00
Revenue This Year
$10.09
$61.57
Revenue Next Year
$12.18
$41.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
110.47
52 Week Low
$13.46
$0.49
52 Week High
$31.04
$3.07

Technical Indicators

Market Signals
Indicator
FLGT
IVVD
Relative Strength Index (RSI) 72.34 41.63
Support Level $13.91 $0.73
Resistance Level $23.70 $1.01
Average True Range (ATR) 0.63 0.09
MACD 0.19 0.01
Stochastic Oscillator 90.42 58.77

Price Performance

Historical Comparison
FLGT
IVVD

About FLGT Fulgent Genetics Inc.

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.

About IVVD Invivyd Inc.

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Share on Social Networks: